Glass House Brands (GLAS) Cash from Financing Activities (2020 - 2026)

Glass House Brands' (GLAS) quarterly Cash from Financing Activities came in at $19.1 million in Q1 2026, up 288.08% year-on-year from $4.9 million in Q1 2025, and up 3619.93% on a QoQ basis from -$542000.0 in Q4 2025.

Glass House Brands (GLAS) Cash from Financing Activities (2020 - 2026) Analysis & Trends

Glass House Brands (GLAS) has 7 years of Cash from Financing Activities data on file, last reported at $19.1 million in Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 288.08% year-over-year to $19.1 million in Q1 2026; TTM through Mar 2026 was $16.9 million, a 441.3% increase from a year earlier, with the FY2025 full-year figure at $2.7 million, up 119.87% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at $19.1 million, up from -$542000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for GLAS reached as high as $8421.8 billion in Q3 2023 and fell as low as -$779.1 billion in Q4 2022.
  • Historically, Cash from Financing Activities has averaged $449.6 billion across 5 years, with a median of $551000.0 in 2023.
  • Across the five-year window, Cash from Financing Activities jumped 100895742.82% in 2023 and sank 784.03% in 2024, its largest moves.
  • Year by year, Cash from Financing Activities stood at -$779.1 billion in 2022, then jumped by 100.0% to $551000.0 in 2023, then sank by 784.03% to -$3.8 million in 2024, then jumped by 85.62% to -$542000.0 in 2025, then surged by 3619.93% to $19.1 million in 2026.
  • Per Business Quant data, the three most recent Cash from Financing Activities figures were $19.1 million in Q1 2026, -$542000.0 in Q4 2025, and $231000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn 13.00 Mn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn -840.00 Mn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn -494.13 Mn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn -1.48 Bn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn -203.80 Mn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn -86.10 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn -65.00 Mn
10 Glass House Brands 873.84 Mn 845.91 Mn 10.02 Mn 19.08 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 19.08 Mn
Mar 31, 2026 19.08 Mn
Dec 31, 2025 -542,000.00
Dec 31, 2025 -542,000.00
Sep 30, 2025 231,000.00
Sep 30, 2025 231,000.00
Jun 30, 2025 -1.88 Mn
Jun 30, 2025 -1.88 Mn
Mar 31, 2025 4.92 Mn
Mar 31, 2025 4.92 Mn
Dec 31, 2024 -3.77 Mn
Dec 31, 2024 -3.77 Mn
Sep 30, 2024 -2.58 Mn
Sep 30, 2024 -2.58 Mn
Jun 30, 2024 -3.52 Mn
Jun 30, 2024 -3.52 Mn
Mar 31, 2024 -3.84 Mn
Mar 31, 2024 -3.84 Mn
Dec 31, 2023 551,000.00
Dec 31, 2023 551,000.00